New combo therapy shows promise in Hard-to-Treat pancreatic cancer
NCT ID NCT03767582
First seen Nov 01, 2025 · Last updated Jun 08, 2026 · Updated 25 times
Summary
This study tested a combination of three drugs (nivolumab, BMS-813160, and GVAX) in 22 people with locally advanced pancreatic cancer who had already received chemotherapy and radiation. The goal was to see if the treatment was safe and could help the immune system better attack the tumor. While the approach aims to control the disease, it is not a cure, and ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.